Social Europe

politics, economy and employment & labour

  • Themes
    • Global cities
    • Strategic autonomy
    • War in Ukraine
    • European digital sphere
    • Recovery and resilience
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Podcast
  • Videos
  • Newsletter
  • Membership

Pandemic preparedness: new vaccines are not enough

Maurizia Mezza and Stuart Blume 23rd February 2023

Rapid deployment of vaccines is the key lesson being taken from the Covid-19 pandemic. It should not be the only one.

vaccines,pandemic
… and it worked: trust is as important as technical progress in vaccine development (Drazen Zigic / shutterstock.com)

Now Covid-19 has been displaced from media headlines by war and natural disasters, most people are happy to forget about viruses. Virologists, however, are worried by rapidly-spreading bird flu and the countless other viruses with the potential to infect and spread among mammals—potentially including humans.

Partly due to ecological deterioration and climate change, the risk of such zoonotic disease outbreaks is indeed growing. The need to prepare for a possible future pandemic is widely accepted, although no one can predict its onset. Nor is it clear which kind of virus might be involved. The experience with SARS-CoV-2 over the past two to three years should however be drawn upon.

Record time

Crucial to control of the Covid-19 pandemic was the development, testing and production of vaccines in record time: it was a mere 326 days from release of the virus’ genetic sequence to authorisation of the first vaccines. This lesson, already being drawn, plays into widespread faith in technological solutions to social and environmental problems.

For the Oslo-based Coalition for Epidemic Preparedness Innovations, speed of vaccine development is indeed key. At the end of 2022, CEPI issued a report detailing how future pandemic-beating vaccines could be produced in just 100 days.


Become part of our Community of Thought Leaders


Get fresh perspectives delivered straight to your inbox. Sign up for our newsletter to receive thought-provoking opinion articles and expert analysis on the most pressing political, economic and social issues of our time. Join our community of engaged readers and be a part of the conversation.

Sign up here

Other lessons which can and should be drawn from the Covid-19 experience cannot however count on similar support. In 2020, before a vaccine became available, the constant refrain was ‘when there’s a vaccine life will return to normal’. The socially and politically complex questions which would still have to be tackled, though foreseeable, were ignored.

These included inequitable access to vaccines, liability in the event of vaccine-related injury, and vaccine refusal and hesitancy. Policy-makers began to address these issues only later, when vaccination campaigns were well under way in much of the world.

Now there is a risk that epidemic preparedness is again being dominated by a single-minded focus on technological solutions. This despite evidence that in Europe public confidence in vaccines and vaccination is actually falling: people are less convinced now than before that vaccines are safe and effective. Unwillingness to accept a Covid-19 vaccine was often due to fear of side-effects. Where is reassurance to come from?

Pharmacovigilance

Post-marketing detection, analysis and prevention of adverse effects of a vaccine or a drug is known as pharmacovigilance. Pharmacovigilance observes the way medicines work in real-life settings and their risk-benefit balance. The pharmacovigilance of vaccines thus monitors adverse events and safety issues that emerge after the vaccine has been approved. This can lead to modification of the group for whom the vaccine is recommended and potentially its withdrawal from the market.

Eudravigilance was established in 2001 as a system for managing and analysing information on suspected adverse drug reactions (ADRs) across the European Economic Area. Pharmacovigilance systems played an important role during the Covid-19 pandemic.

Until recently, national pharmacovigilance centres collected reports on ADRs only from healthcare professionals and pharmaceutical companies. In 2003, Denmark and the Netherlands became the first countries to allow patients and consumers to report suspected ADRs directly. Italy (2004), the United Kingdom (2005) and Sweden (2008) followed suit.

Key insights

Research shows that that ADRs can be identified and described sooner by consumers and patients themselves. Their reports can provide key insights regarding drug-related problems. Since 2012, EU-wide legislation has required that patients be able to report suspected ADRs to competent authorities.

A recent review of Dutch experience of public participation in pharmacovigilance was very positive. A review in the UK showed growing numbers of ADRs identified by patients. Yet enabling patients to report does not mean that they will do so. The literature shows that many are not aware they can report or where they should do so.


Support Progressive Ideas: Become a Social Europe Member!


Support independent publishing and progressive ideas by becoming a Social Europe member for less than 5 Euro per month. You can help us create more high-quality articles, podcasts and videos that challenge conventional thinking and foster a more informed and democratic society. Join us in our mission - your support makes all the difference!

Become a Social Europe Member

The number of reports submitted directly by patients and consumers to Eudravigilance rose more than five-fold (+443 per cent) between 2020 and 2021. Reports related to Covid-19 vaccines accounted for 87 per cent of these. Nevertheless, in much of the world direct patient reporting remains an unfamiliar practice.

Pharmacovigilance agencies have introduced new reporting tools, including mobile applications. While these have led to more reports, this is still not enough. Building mutual trust requires more, and patient engagement should go beyond providing personal data.

Important role

Pharmacovigilance is not acknowledged as the key component of epidemic preparedness it ought to be. Pharmacovigilance centres must engage with civil society—and not only as a source of data. Information has to flow both ways, and in this patient and health-advocacy organisations could play an important role. What information regarding possible adverse events would the public like to see collected? Do people trust that their reports are taken seriously? What kind of feedback or reporting to the community would be best?

Responses to the Covid-19 pandemic have shown the value of a well-functioning pharmacovigilance system.Yet this is still far from being a democratic, transparent and accessible space where civil society can negotiate rights and duties. Most studies of pharmacovigilance in practice focus on ways of enhancing statistical confidence in causal relationships between a vaccine and any associated symptoms.

But public confidence is not the same as statistical confidence. Enhancing pharmacovigilance systems, and supporting civil society’s participation in them, should be an important part of epidemic preparedness. What will be the value of having a vaccine in less than 100 days if many citizens do not trust it?

Maurizia Mezza
Maurizia Mezza

Maurizia Mezza is a doctoral candidate in medical anthropology at the University of Amsterdam, focusing on epidemiological studies and pharmacovigilance in relation to HPV and Covid-19 vaccination.

Stuart Blume
Stuart Blume

Stuart Blume is emeritus professor of science and technology studies at the University of Amsterdam and author of Immunization: How Vaccines Became Controversial (Reaktion Books, 2017).

You are here: Home / Society / Pandemic preparedness: new vaccines are not enough

Most Popular Posts

Russia,information war Russia is winning the information warAiste Merfeldaite
Nanterre,police Nanterre and the suburbs: the lid comes offJoseph Downing
Russia,nuclear Russia’s dangerous nuclear consensusAna Palacio
Belarus,Lithuania A tale of two countries: Belarus and LithuaniaThorvaldur Gylfason and Eduard Hochreiter
retirement,Finland,ageing,pension,reform Late retirement: possible for many, not for allKati Kuitto

Most Recent Posts

Nagorno-Karabakh,European Union,EU,Azerbaijan,Armenia Azerbaijan exploits vacuum on Nagorno-KarabakhGeorge Meneshian
Abuse,work,workplace,violence Abuse at work: who bears the brunt?Agnès Parent-Thirion and Viginta Ivaskaite-Tamosiune
Ukraine,fatigue Ukraine’s cause: momentum is diminishingStefan Wolff and Tetyana Malyarenko
Vienna,social housing Vienna social-housing model: celebrated but misusedGabu Heindl
social democracy,nation-state Social democracy versus the nativist rightJan Zielonka

Other Social Europe Publications

strategic autonomy Strategic autonomy
Bildschirmfoto 2023 05 08 um 21.36.25 scaled 1 RE No. 13: Failed Market Approaches to Long-Term Care
front cover Towards a social-democratic century?
Cover e1655225066994 National recovery and resilience plans
Untitled design The transatlantic relationship

Hans Böckler Stiftung Advertisement

WSI European Collective Bargaining Report 2022 / 2023

With real wages falling by 4 per cent in 2022, workers in the European Union suffered an unprecedented loss in purchasing power. The reason for this was the rapid increase in consumer prices, behind which nominal wage growth fell significantly. Meanwhile, inflation is no longer driven by energy import prices, but by domestic factors. The increased profit margins of companies are a major reason for persistent inflation. In this difficult environment, trade unions are faced with the challenge of securing real wages—and companies have the responsibility of making their contribution to returning to the path of political stability by reducing excess profits.


DOWNLOAD HERE

ETUI advertisement

The future of remote work

The 12 chapters collected in this volume provide a multidisciplinary perspective on the impact and the future trajectories of remote work, from the nexus between the location from where work is performed and how it is performed to how remote locations may affect the way work is managed and organised, as well as the applicability of existing legislation. Additional questions concern remote work’s environmental and social impact and the rapidly changing nature of the relationship between work and life.


AVAILABLE HERE

Eurofound advertisement

Eurofound Talks: does Europe have the skills it needs for a changing economy?

In this episode of the Eurofound Talks podcast, Mary McCaughey speaks with Eurofound’s research manager, Tina Weber, its senior research manager, Gijs van Houten, and Giovanni Russo, senior expert at CEDEFOP (The European Centre for the Development of Vocational Training), about Europe’s skills challenges and what can be done to help workers and businesses adapt to future skills demands.

Listen where you get your podcasts, or for free, by clicking on the link below


LISTEN HERE

Foundation for European Progressive Studies Advertisement

The summer issue of the Progressive Post magazine by FEPS is out!

The Special Coverage of this new edition is dedicated to the importance of biodiversity, not only as a good in itself but also for the very existence of humankind. We need a paradigm change in the mostly utilitarian relation humans have with nature.

In this issue, we also look at the hazards of unregulated artificial intelligence, explore the shortcomings of the EU's approach to migration and asylum management, and analyse the social downside of the EU's current ethnically-focused Roma policy.


DOWNLOAD HERE

About Social Europe

Our Mission

Article Submission

Membership

Advertisements

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Social Europe Archives

Search Social Europe

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Follow us

RSS Feed

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on YouTube